Long-term follow-up after receiving HMI 102
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study checks how people are doing long-term after they previously received a treatment called HMI 102. It may help researchers understand long-term safety and outcomes so future patients can be better supported.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received HMI 102 in an earlier study or treatment
- You can understand the study and agree to participate by signing consent
- You are able and willing to follow the study’s schedule and instructions over the long term
- Your study doctor feels participation is in your best interest
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who already completed a previous trial of GLM101 for PMM2-CDG. It offers continued access to the treatment while doctors monitor safety and effects.
This study is a long-term follow-up for people who already received an experimental treatment called MB-105 in a previous study. It helps researchers see how you're doing over time and collect extra information about the treatment's lasting effects.
This is a follow-up study for people who already took JR-141 in an earlier trial for Hunter syndrome (MPS II). It checks how well the treatment works over the long term and monitors long-term safety.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This trial tests a medicine called HDM1002 in people who have different levels of liver function. It aims to see how the liver affects the drug and if it is safe.
Hear when a new Phenylketonuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.